Author:
Shen Jiale,Wang Jiarui,Wu Meng,Shi Yan,Lee Minhyeock,Wang Zhiguo,Kong Ming
Abstract
AbstractEczema is a common chronic dermatological disease. Conventional treatments exhibit limited efficacy due to fast drug release resulting in short-term relief. Development of a new treatment strategy that enables sustained drug release and long-term maintenance on the skin surface is necessary. A self-adhesive swelling microneedle patch (SDSMNs) was designed and constructed using a two-step casting method. The adhesive substrate was prepared by blending gelatin and dopamine via oxidation of NaIO4, so it could adhere onto the skin surface as well as withstand repeated bending movement without detachment. The swelling needles were fabricated using polyvinyl alcohol (PVA) and polyvinylpyrrolidone (PVP), which could swell by absorbing interstitial fluid and release the drug in a controlled manner. SDSMNs also showed desirable antibacterial activities toward E. coli and S. aureus. The adhesive microneedles loaded with matrine (MAT-SDSMNs), an anti-inflammatory Chinese medicine, dramatically relieved eczema symptoms through IL-17 mediated inflammation responses. The use of MAT-SDSMNs significantly decreased the infiltration of inflammation cells and level of inflammatory cytokines, reduced the skin thickness, and increased collagen deposition fraction compared with conventional ointment or subcutaneous injection. The results suggested that MAT-SDSMNs can improve eczema treatment by regulating the local inflammatory microenvironment, providing a simple, self-administered sustainable strategy for eczema treatment.
Publisher
Springer Science and Business Media LLC
Reference30 articles.
1. Ahmad SF, Zoheir KMA, Ansari MA, Nadeem A, Bakheet SA, AL-Ayadhi LY, Alzahrani MZ, Al-Shabanah OA, Al-Harbi MM, Attia SM (2017) Dysregulation of Th1, Th2, Th17, and T regulatory cell-related transcription factor signaling in children with autism. Mol Neurobiol 54:4390–4400
2. Andersen RM, Thyssen JP, Maibach HI (2016) Qualitative vs quantitative atopic dermatitis criteria - in historical and present perspectives. J Eur Acad Dermatol 30:604–618
3. Azizi G, Rastegar Pouyani M, Navabi SS, Yazdani R, Kiaee F, Mirshafiey A (2015) The newly identified T helper 22 cells lodge in leukemia. Int J Hematol Oncol Stem Cell Res 9:143–154
4. Carello R, Ricottini L, Miranda V, Panei P, Rocchi L, Arcieri R, Galli E (2017) Long-term treatment with low-dose medicine in chronic childhood eczema. A double-blind two-stage randomized control trial. Ital J Pediatr 72:312–312
5. Dourmishev LA, Mironova NY (2021) Atopic dermatitis: from etiology and history to treatment. Acta Medica Bulgarica 48:68–76